Metrics as of 10/13/2026, 06:49 PM (Berlin time), refresh in progress.
Big Pharma Split Stock
Big Pharma Split Corp.
Company data
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- Canada
- CEO
- Louis Michael Kovacs
- Market cap
- $20 M
- IPO
- 27/11/2017
Big Pharma Split Corp, a closed-end equity investment fund, was established on September 15, 2017, and maintains its domicile in Canada. Overseen by Harvest Portfolios Group Inc., the fund concentrates its investments primarily within the pharmaceutical sector, targeting publicly traded companies across the United…
Big Pharma Split stock: price history
1D
+2.9%
1W
+4.8%
1M
+1.7%
6M
+5.2%
YTD
+7.8%
1Y
+21.0%
2Y
+5.5%
5Y
+11.0%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Big Pharma Split
Big Pharma Split stock metrics
P/E
2.76
P/B
1.02
EV/EBITDA
6.05
RETURN ON EQUITY
9.6%
NET MARGIN
48.0%
DEBT/EQUITY
0.67
DIVIDEND YIELD
8.3%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
100.5%
FLOAT SHARES
1,310,978
AVG. DAILY VOLUME (30D)
1,297
Dividends
Comparable stocks
Frequently asked questions about Big Pharma Split stock
What does Big Pharma Split do?
Big Pharma Split Corp. is a company in the Financial Services sector, Asset Management industry, headquartered in Canada.
The IPO was on 27/11/2017; the stock trades on TSX under the ticker PRM.TO.
When does Big Pharma Split report next?
Around past earnings, price swings were roughly 7% stronger than usual.
Does Big Pharma Split pay a dividend?
Yes. The last dividend was CA$0.10 per share, ex-date 29/09/2026, paid on 06/10/2026.
The dividend yield is 8.3% (as of 30/06/2026).
Which stocks are comparable to Big Pharma Split?
Comparable stocks include BlackRock, Blackstone, KKR &, Apollo Global Management, State Street, Ameriprise Financial, Ares Management and Northern Trust.
How can I get Big Pharma Split stock analyzed?
Clicking "Analyze stock" lets five strategies assess Big Pharma Split against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.